<DOC>
	<DOC>NCT00472004</DOC>
	<brief_summary>This is a Phase IV prospective, randomized, open label, comparative, multicenter study in generally healthy postmenopausal women receiving Totelle (17B Estradiol/TMG CC (1mg)) and Livial (Tibolone).</brief_summary>
	<brief_title>Study Comparing 17B Estradiol/TMG CC 1mg Vs. Tibolone In Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Tibolone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Generally healthy postmenopausal women Last natural (without exogenous hormone therapy) menstrual cycle completed at least 12 consecutive months prior to screening and without any other kind of gynecological bleeding during this same period At least 1 year of natural occurring amenorrhea Known or suspected estrogendependent neoplasia Endometrial hyperplasia Any malignancy with the exception of a history of basal cell carcinoma of the skin</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>